PARIS, FRANCE — July 4, 2002 –
An induction regimen of infliximab rapidly clears psoriatic skin lesions and is well tolerated, investigators say. Dr. Rudolf E. Schopf, with Johannes Gutenberg University in Mainz,
Germany, presented the findings here at the 20th World Congress of Dermatology (WCD). Infliximab (Remicade), a chimeric monoclonal antibody that inhibits tumour necrosis factor-alpha (TNF-a), binds to the soluble and transmembrane forms of TNF-a and inhibits the binding of TNF-a with its receptors.
Concurrent improvement of psoriatic skin lesions with infliximab had been noted in earlier series in patients treated with infliximab for other skin conditions. Dr. Schopf and colleagues conducted an open-label study of eight patients with moderate to severe psoriasis who were treated with open-label infliximab 5 mg/kg. No systemic anti-psoriatic or anti-inflammatory therapy was administered within four weeks of the start of the study.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!